MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David Cathcart who wrote (760)	3/4/1998 11:13:00 PM
From: Biomaven	Read Replies (2) of 1826

<<This may mean leukemia because its easier to study (patient's blood samples are rapidly analyzed)>> which would make Richard Bagnell's question about the recent paper on MGI-114's mode of action somewhat prescient: <<So why was all this work done on the CEM, human leukemia, cell line? Why not select a cell line used before (MX-1 breast carcinoma, MCF7 breast adenocarcinoma , MV522 lung, HT-29 colon, etc.)? Why not select the cell type you expect to study in Phase II clinical trials?>> Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next